RxDoctor Payments Data

Ugochi Ekemezie

Psychiatric/Mental Health · Lawrenceville, NJNPI 1235539420

Payments from drug & device makers

$1,044in general payments, 2019–2025

Across 66 payments — averaging $15.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$323
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$310
  • Teva Pharmaceuticals USA, Inc.$159
  • AbbVie$103
  • Neurocrine Biosciences, Inc.$60
  • E.r. Squibb & Sons, L.L.C.$55
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$1,03299%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,044 in reported general payments places this provider in the 65th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$7,715
Medicare patients
19
Services billed
89

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega TrinzaPaliperidone Palmitate11$71,959
Invega SustennaPaliperidone Palmitate14$44,865
CaplytaLumateperone Tosylate12$23,094
GeodonZiprasidone Hcl12$20,080
VraylarCariprazine Hcl14$18,963
Lurasidone Hcl13$3,837
Venlafaxine Hcl ErVenlafaxine Hcl58$2,601
Quetiapine Fumarate135$1,772
Chlorpromazine Hcl26$1,354
Haloperidol Decanoate22$1,349
Quetiapine Fumarate ErQuetiapine Fumarate26$713
Duloxetine Hcl53$628
Lamotrigine48$604
Bupropion XlBupropion Hcl21$527
Aripiprazole33$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Trinza, Invega Sustenna$323$116,82525 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$310$23,09412 claims
AbbVieVraylar$103$18,96314 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Lawrenceville

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →